🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Phase 2 study shows intravesical durvalumab is safe and tolerable after BCG failure, with a 1-yr HGR-free rate of 39%. Superior tolerability compared to systemic administration (see table below). #BladderCancer European Association of Urology (EAU) pubmed.ncbi.nlm.nih.gov/39827021/

Good stuff from European Association of Urology (EAU) today: REBACARE trial shows preop MMC reduces #bladdercancer recurrence—but only in patients without prior ureteroscopy. Raises a fair question: Is URS harmful? Need to see how distribution varies by baseline characteristics. pubmed.ncbi.nlm.nih.gov/39843302/

Amer. Urol. Assn. 2025 Annual Meeting - BOND-003 Cohort C: listen to our podcast with Mark Tyson on this conditionally replicating adenovirus in BCG-unresponsive NMIBC. spotifycreators-web.app.link/e/JkEwxljnUSb jim catto Prof. Prokar Dasgupta OBE Professor Henry Woo Phillip Pierorazio Scott Eggener Mohamad Allaf Samir Taneja

CR rate with Cretostimogene Grenadenorepvec for High-Risk BCG- Unresponsive NMIBC with CIS in BOND-003. #MedIQAUA25 #AUA25 #bladdercancer Mark Tyson

And … we did it! Thanks to everyone who showed up – not just to engage with the latest and cutting-edge debates in bladder cancer, but most importantly, to stand in support of our patients. AUA-IBCG Bladder Cancer Forum #AUA25 Amer. Urol. Assn. IBCG Kelly Bree

So happy and proud to share our recent publication on the much talked about topic of Bladder Preservation in NMIBC/MIBC, under the expert mentorship of Dr. Singh. Truly grateful for Dr. Singh’s guidance 🙏🏻😊😇. Parminder singh Mark Tyson Adri Durant link.springer.com/article/10.100…

Totally agree! Leslie Ballas Mark Tyson Abhishek Tripathi Bladder Cancer Advocacy Network

BCG > gem for LG IR-NMIBC (better RFS); RARC = ORC (RAZOR: no diff in major comps/readmits —>frailty is the key); bilateral > unilateral primary RPLND for stage II seminoma (cuts RP relapse, ~15% crossover). Good stuff in Journal of Urology this month: auajournals.org/toc/juro/213/6